The Sage Group Announces $100M+ Transaction between medac GmbH and Medexus Pharma for Trecondi
The Sage Group Inc. served as exclusive advisor to medac GmbH on this $100M+ transaction.
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
